Press release -
Successful presence at cell and gene therapy meet
Last week Vironova attended the 26th annual meeting of the European Society of Gene and Cell Therapy (ESGCT) in Lausanne, Switzerland. The congress highlighted the latest research, techniques and developments in this field of gene and cell therapy, bringing together scientists from throughout Europe and beyond.
Vironova participated in the poster presentations, presenting their latest work on the characterization of AAV gene therapy viral vectors.
A copy of the poster “Characterization of AAV gene therapy viral vectors: packaging, purity and integrity using Transmission Electron Microscopy” can be requested using the contact form on our website.
Topics
- Medical research
Categories
- minitem
- tem
- vironova
Vironova is a Swedish biotechnology company providing comprehensive, hardware, software and services for the analysis of nanoparticles. Vironova revolutionizes access to transmission electron microscopy (TEM)-based image analysis in biopharmaceutical development. Our solution enables automated analyses for faster and better-informed decisions to secure robust bioprocessing and final product quality.
The Vironova offering comprises:
- Cost effective, fast Electron Microscopy (EM) services enabled by the in-house developed Vironova Analyzing Software (VAS) designed for semi-automated nanoparticle analysis
- Viral clearance testing performed in GLP and BSLIII certified laboratories
- MiniTEM™, a bench-top Transmission Electron Microscope system designed for automated nanoparticle characterization. High-resolution images reveal particle morphologies that are transformed into accurate metrics.
